This invention provides compounds of Formula I having the structure:
##STR00001## wherein: B is alkyl of 1-4 carbons or alkoxy of 1-4
carbons; R.sub.1 is aryl or Het optionally substituted with R.sub.6;
R.sub.2 and R.sub.3 are each independently, alkyl of 1-4 carbons,
CF.sub.3, aryl or Het substituted with R.sub.6, or R.sub.2 and R.sub.3
are combined to form a cycloalkyl or heterocyclic ring optionally
substituted with alkyl, benzyl, or acyl; R.sub.4, and R.sub.5 are each
independently, hydrogen, halogen, alkyl of 1-4 carbons, CO.sub.2R.sub.7,
SO.sub.2NHR.sub.7, CONHR.sub.7, CN, NO.sub.2 or CF.sub.3; R.sub.6 is
hydrogen, halogen, NO.sub.2, alkyl of 1-4 carbons, alkoxy of 1-4 carbons,
alkylcarbonyloxy of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms,
CF.sub.3, or COOH; and R.sub.7 is hydrogen, alkyl of 1-4 carbons, or
alkylaryl where aryl group is substituted with R.sub.6; or a
pharmaceutically acceptable salt thereof, which are useful in treating
metabolic disorders related to insulin resistance or hyperglycemia.